AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET ANALYSIS

Autism Spectrum Disorder Therapeutics Market, by Drug Type (Aripiprazole, Risperidone, Melatonin, CM-AT, Bumetanide, and Balovaptan), by Age Group (Child and Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Published In : Dec 2019
Code : CMI2643
Pages :308
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Autism Spectrum Disorder Therapeutics Market - Regional Insights

On the basis of region, the global autism spectrum disorder therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global autism spectrum disorder therapeutics market during the forecast period, owing to increasing prevalence of ASD in the pediatric population of the U.S. For instance, according to the Centers for Disease Control and Prevention’s (CDC) report released in April 2018, 1 in every 59 children was identified with ASD in the age range of 3 to 17 years in 2014.

Asia Pacific is expected to foresee a rapid growth in the autism spectrum disorder therapeutics market revenue. This is owing to increase in sales of Aripiprazole for the treatment of ASD. For instance, in 2017, Otsuka Pharmaceutical’s ABILIFY MAINTENA (Aripiprazole) generated US$ 62.9 million in revenue with a growth of 24.1% compared to the revenue in 2016. Moreover, ABILIFY accounted for a revenue of US$ 59.7 million in 2017.

Autism Spectrum Disorder Therapeutics Market Report Snapshots